123 related articles for article (PubMed ID: 10210109)
1. Cathepsin B, p53 expression and AgNORs in transitional cell carcinoma.
Akpolat I; Bariş YS; Yilmaz AF; Bakirtaş M; Saylik A; Karagöz F; Kandemir B
Neoplasma; 1998; 45(6):365-8. PubMed ID: 10210109
[TBL] [Abstract][Full Text] [Related]
2. Argyrophilic nucleolar organizer region in proliferating cell has a predictive value for local recurrence in superficial bladder tumor.
Tomobe M; Shimazui T; Uchida K; Hinotsu S; Akaza H
J Urol; 1999 Jul; 162(1):63-8. PubMed ID: 10379741
[TBL] [Abstract][Full Text] [Related]
3. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
[TBL] [Abstract][Full Text] [Related]
5. Role of the argyrophilic nucleolar organizer regions in tumor detection and prognosis.
Pich A; Chiusa L; Margaria E
Cancer Detect Prev; 1995; 19(3):282-91. PubMed ID: 7750118
[TBL] [Abstract][Full Text] [Related]
6. Nucleolar organizer region in transitional cell carcinoma of the bladder.
Pisac VP; Krizanac S; Andelinović S
Acta Med Croatica; 1997; 51(2):83-6. PubMed ID: 9204592
[TBL] [Abstract][Full Text] [Related]
7. Argyrophilic nucleolar organizer regions (AgNORs) in relation to p53 and bcl-2 protein expression in leukemia patients.
Klobusická M; Kusenda J; Babusíková O
Neoplasma; 2003; 50(6):408-15. PubMed ID: 14689061
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
[TBL] [Abstract][Full Text] [Related]
9. Relationship between AgNORs, MIB-1 and oncogene expression in male breast carcinoma and papillary superficial bladder neoplasm.
Pich A; Margaria E; Chiusa L; Bortolin P; Palestro G
Oncol Rep; 2003; 10(5):1329-35. PubMed ID: 12883702
[TBL] [Abstract][Full Text] [Related]
10. [Nucleolar organizer region in bladder cancer. Relationship with histologic grade, stage, and prognosis].
Rivera P; Roa I
Actas Urol Esp; 1994 Mar; 18(3):204-6. PubMed ID: 8036947
[TBL] [Abstract][Full Text] [Related]
11. Lack of prognostic value of nucleolar organizer region enumeration in transitional cell carcinoma of the bladder.
Mansour P; Crocker J; Newman J
Arch Pathol Lab Med; 1990 Dec; 114(12):1261. PubMed ID: 1701296
[TBL] [Abstract][Full Text] [Related]
12. Two-dimensional agnor evaluation as a prognostic variable in urinary bladder carcinoma: a different approach via total agnor area/nucleus area per cell.
Cucer N; Imamoglu N; Tozak H; Demirtas H; Sarac F; Tatlisen A; Oztürk F
Micron; 2007; 38(6):674-9. PubMed ID: 17011198
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
Dekairelle AF; Tombal B; Cosyns JP; Gala JL
Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
[TBL] [Abstract][Full Text] [Related]
16. AgNOR/P53 expression compared with different grades in bladder carcinoma.
Karakök M; Aydin A; Bakir K; Uçak R; Korkmaz C
Int Urol Nephrol; 2001; 33(2):353-5. PubMed ID: 12092655
[TBL] [Abstract][Full Text] [Related]
17. [Immunohistochemical study of p53 and Ki-67 antigen expression in bladder carcinoma].
Yuge F; Hirakata H; Igarashi H; Kodama M; Kawata N; Takimoto Y
Hinyokika Kiyo; 1999 Jul; 45(7):453-6. PubMed ID: 10466059
[TBL] [Abstract][Full Text] [Related]
18. High expression of cathepsin B in transitional bladder carcinoma correlates with tumor invasion.
Eiján AM; Sandes EO; Riveros MD; Thompson S; Pasik L; Mallagrino H; Celeste F; Casabé AR
Cancer; 2003 Jul; 98(2):262-8. PubMed ID: 12872343
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
20. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
